- Home
- NUVB vs VMEO Comparison
NUVB vs VMEO Comparison
Compare NUVB & VMEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVB
- VMEO
- Stock Information
- Founded
- NUVB 2018
- VMEO 2004
- Country
- NUVB United States
- VMEO United States
- Employees
- NUVB N/A
- VMEO N/A
- Industry
- NUVB Biotechnology: Pharmaceutical Preparations
- VMEO Computer Software: Prepackaged Software
- Sector
- NUVB Health Care
- VMEO Technology
- Exchange
- NUVB Nasdaq
- VMEO Nasdaq
- Market Cap
- NUVB 1.1B
- VMEO 652.9M
- IPO Year
- NUVB N/A
- VMEO N/A
- Fundamental
- Price
- NUVB $3.18
- VMEO $7.75
- Analyst Decision
- NUVB Strong Buy
- VMEO Hold
- Analyst Count
- NUVB 6
- VMEO 4
- Target Price
- NUVB $8.17
- VMEO $6.81
- AVG Volume (30 Days)
- NUVB 6.7M
- VMEO 6.4M
- Earning Date
- NUVB 11-05-2025
- VMEO 11-03-2025
- Dividend Yield
- NUVB N/A
- VMEO N/A
- EPS Growth
- NUVB N/A
- VMEO N/A
- EPS
- NUVB N/A
- VMEO 0.08
- Revenue
- NUVB $14,355,000.00
- VMEO $415,404,000.00
- Revenue This Year
- NUVB $332.80
- VMEO $3.31
- Revenue Next Year
- NUVB $360.12
- VMEO $5.76
- P/E Ratio
- NUVB N/A
- VMEO $100.95
- Revenue Growth
- NUVB 900.35
- VMEO N/A
- 52 Week Low
- NUVB $1.54
- VMEO $3.64
- 52 Week High
- NUVB $4.09
- VMEO $7.90
- Technical
- Relative Strength Index (RSI)
- NUVB 55.01
- VMEO 91.34
- Support Level
- NUVB $3.20
- VMEO $4.03
- Resistance Level
- NUVB $3.41
- VMEO $7.78
- Average True Range (ATR)
- NUVB 0.28
- VMEO 0.10
- MACD
- NUVB -0.04
- VMEO 0.30
- Stochastic Oscillator
- NUVB 26.17
- VMEO 98.93
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
About VMEO Vimeo Inc.
Vimeo Inc is the all-in-one video software solution, providing the full breadth of video tools through a software-as-a-service model. The comprehensive and cloud-based tools of the company empower its users to create, share, collaborate and communicate with video on a single, turnkey platform. The company derives its revenue from SaaS subscription fees paid by customers for subscription plans.